414 related articles for article (PubMed ID: 27306093)
1. Effects and Role of Multikinase Inhibitors in Thyroid Cancer.
Laursen R; Wehland M; Kopp S; Pietsch J; Infanger M; Grosse J; Grimm D
Curr Pharm Des; 2016; 22(39):5915-5926. PubMed ID: 27306093
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
3. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
4. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
[No Abstract] [Full Text] [Related]
5. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
Hegazi M; Azadi A; Jain D; Redman R; Perez CA
Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
[TBL] [Abstract][Full Text] [Related]
6. Questions and Controversies in the Clinical Application of Tyrosine Kinase Inhibitors to Treat Patients with Radioiodine-Refractory Differentiated Thyroid Carcinoma: Expert Perspectives.
Verburg FA; Amthauer H; Binse I; Brink I; Buck A; Darr A; Dierks C; Koch C; König U; Kreissl MC; Luster M; Reuter C; Scheidhauer K; Willenberg HS; Zielke A; Schott M
Horm Metab Res; 2021 Mar; 53(3):149-160. PubMed ID: 33652491
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT; Cohen EE
Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
Felicetti F; Nervo A; Piovesan A; Berardelli R; Marchisio F; Gallo M; Arvat E
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1093-1098. PubMed ID: 28988510
[TBL] [Abstract][Full Text] [Related]
11. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
12. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
13. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.
Anderson RT; Linnehan JE; Tongbram V; Keating K; Wirth LJ
Thyroid; 2013 Apr; 23(4):392-407. PubMed ID: 23294230
[TBL] [Abstract][Full Text] [Related]
14. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.
Costa R; Carneiro BA; Chandra S; Pai SG; Chae YK; Kaplan JB; Garrett HB; Agulnik M; Kopp PA; Giles FJ
Drug Des Devel Ther; 2016; 10():873-84. PubMed ID: 27013865
[TBL] [Abstract][Full Text] [Related]
15. Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension.
Kaae AC; Kreissl MC; Krüger M; Infanger M; Grimm D; Wehland M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830100
[TBL] [Abstract][Full Text] [Related]
16. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
17. Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease.
Mischler K; Kneifel S; Cathomas R
Oncol Res Treat; 2016; 39(9):548-52. PubMed ID: 27614988
[TBL] [Abstract][Full Text] [Related]
18. Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study.
Iwasaki H; Yamazaki H; Takasaki H; Suganuma N; Sakai R; Nakayama H; Toda S; Masudo K
Medicine (Baltimore); 2019 Oct; 98(42):e17588. PubMed ID: 31626129
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
Fleeman N; Houten R; Chaplin M; Beale S; Boland A; Dundar Y; Greenhalgh J; Duarte R; Shenoy A
BMC Cancer; 2019 Dec; 19(1):1209. PubMed ID: 31830943
[TBL] [Abstract][Full Text] [Related]
20. Multikinase Inhibitor Treatment in Thyroid Cancer.
Ancker OV; Krüger M; Wehland M; Infanger M; Grimm D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]